ArticleCurrent medical science2026
Screening and Functional Validation of Common Key Genes in Hypertrophic Cardiomyopathy and Ischemic Cardiomyopathy.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveHypertrophic cardiomyopathy (HCM) and ischemic cardiomyopathy (ICM) are the most common main etiologies of heart failure (HF), which is also a leading cause of mortality and morbidity; however, the common mechanisms triggering the gradual progression and evolution of HF have not yet been fully elucidated. Hence, the purpose of this study focuses on the communal biological mechanisms involved, screening and functional validation of common key genes.
methodsThe gene expression profiles of HCMs (GSE36961, GSE160997) and ICMs (GSE5406, GSE26887) were downloaded from the Gene Expression Omnibus (GEO) database. After the common genes (CGs) were identified based on the intersection of the differentially expressed genes (DEGs) from the GSE36961 and GSE5406 datasets, pathway enrichment, functional annotation, protein‒protein interaction (PPI) network, hub gene identification, transcription factor (TF)-mRNA regulatory network and diagnostic efficiency evaluation were performed. In addition, the hub genes were verified with the GSE160977 and GSE26887 datasets. These findings ultimately validated the functional role of Bcl6 in both cellular and animal experiments.
resultsIn total, 88 CGs (54 downregulated genes and 34 upregulated genes) were screened for subsequent analyses. Functional annotation and pathway enrichment revealed the important role of angiogenesis in these two diseases. Seven important hub genes were identified, including MYC, STAT3, CEBPB, CEBPD, CDKN1A, BCL6 and MAP2K1. The TF-mRNA network revealed that BCL6, STAT3, MYC and CDKN1A were closely related and might coordinately participate in common biological pathogenesis. Receiver operating characteristic (ROC) curve analysis revealed that the hub genes had great value for clinical diagnostic efficiency. The ROC curve prediction revealed that the optimal indicator in HCM and ICM is the Bcl6 protein. Overexpression of Bcl6 ameliorates cardiac phenotypes in mouse models of both HCM and ICM.
conclusionsOur research revealed the common potential pathogenesis mechanism of HCM and ICM. The identification of these hub genes might provide novel directions for further treatment research, clinical diagnosis and treatment.
Indexed as
Identifiers
41790394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.